TXMD
Therapeuticsmd Inc
NASDAQ · Pharmaceuticals
$2.29
+0.10 (+4.57%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.35M | 4.86M | 6.01M |
| Net Income | 1.38M | 1.27M | 1.34M |
| EPS | — | — | — |
| Profit Margin | 25.7% | 26.2% | 22.4% |
| Rev Growth | +2.2% | +8.5% | +15.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 6.62M | 6.73M | 8.04M |
| Total Equity | 11.70M | 11.85M | 11.59M |
| D/E Ratio | 0.57 | 0.57 | 0.69 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 2.60M | 2.17M | 2.73M |
| Free Cash Flow | 1.75M | 1.08M | 1.44M |